<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577460</url>
  </required_header>
  <id_info>
    <org_study_id>248.634</org_study_id>
    <secondary_id>2007-004235-37</secondary_id>
    <nct_id>NCT00577460</nct_id>
  </id_info>
  <brief_title>Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD</brief_title>
  <official_title>Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim of this study is to obtain long-term safety and tolerability data on
      pramipexole extended release (ER), in daily doses from 0.375mg to 4.5mg once daily (qd), in
      patients who have previously completed a pramipexole double-blind study in advanced
      Parkinson's disease (PD) (248.525 trial).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events</measure>
    <time_frame>80 weeks</time_frame>
    <description>The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in advanced Parkinson's Disease (PD) (248.525 (NCT00466167)). Therefore these items were considered as a safety evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Successfully Switched From Pramipexole (PPX) IR or ER to ER Assessed on UPDRS II+III</measure>
    <time_frame>One week</time_frame>
    <description>Unified Parkinson's Disease Rating Scale (UPDRS) Successfully switched means: UPDRS II+III baseline score &gt;20 without a relative worsening of UPDRS II+III score &gt; 15% from baseline or UPDRS II+III baseline score &lt;=20 without an absolute worsening of UPDRS II+III score &gt; 3 from baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS II+III Change From Open Label (OL) Baseline</measure>
    <time_frame>OL Baseline and week 80</time_frame>
    <description>UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With UPDRS II+III Response</measure>
    <time_frame>Week 80</time_frame>
    <description>A response means an improvement of &gt;=20% in UPDRS II+III from OL baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Successfully Switched From PPX IR or ER to ER Assessed on Off-time</measure>
    <time_frame>One week</time_frame>
    <description>A patient was considered as successfully switched if he/she has converted to ER without a worsening of off time by more than 12.5% from baseline. Off-time is based on patient diary data and describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Off Time During Waking Hours Total Score: Change From Baseline</measure>
    <time_frame>Baseline and week 80</time_frame>
    <description>Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
A negative change implies improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response in Percentage Off Time During Waking Hours</measure>
    <time_frame>80 weeks</time_frame>
    <description>Response means &gt;=20% improvement relative to OL baseline in the % off-time during waking hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage on Time Without Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</measure>
    <time_frame>Baseline and week 80</time_frame>
    <description>Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage on Time With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</measure>
    <time_frame>Baseline and week 80</time_frame>
    <description>Percentage on-time with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage on Time Without Dyskinesia or With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</measure>
    <time_frame>Baseline and week 80</time_frame>
    <description>Percentage on-time without dyskinesia or with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage on Time With Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</measure>
    <time_frame>Baseline and week 80</time_frame>
    <description>Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response in CGI-I</measure>
    <time_frame>32 weeks</time_frame>
    <description>Clinical Global Impression of Improvement (CGI-I), CGI-I scores ranging from '1' (very much improved) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much improved&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much improved were considered as responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response in PGI-I</measure>
    <time_frame>32 weeks</time_frame>
    <description>Patient Global Impression of Improvement (PGI-I), PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response in PGI-I for Early Morning Off Symptoms</measure>
    <time_frame>32 weeks</time_frame>
    <description>Patient Global Impression of Improvement (PGI-I) for early morning off symptoms, PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS I Total Score and Change From OL Baseline at Week 80</measure>
    <time_frame>OL baseline and week 80</time_frame>
    <description>UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS II Total Score and Change From OL Baseline at Week 80</measure>
    <time_frame>OL baseline and week 80</time_frame>
    <description>UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS III Total Score and Change From OL Baseline at Week 80</measure>
    <time_frame>OL baseline and week 80</time_frame>
    <description>UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS IV Total Score and Change From OL Baseline at Week 80</measure>
    <time_frame>OL baseline and week 80</time_frame>
    <description>UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson Fatigue Scale (PFS-16) Score and Change From OL Baseline at Week 80</measure>
    <time_frame>OL baseline and week 80</time_frame>
    <description>PFS-16 (Parkinson fatigue scale) ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With L-dopa Daily Dose Change: Change From OL Baseline at Week 80</measure>
    <time_frame>OL baseline and week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Changes in Pramipexole Doses After 80 Weeks Compared to Pramipexole Dose at OL Baseline</measure>
    <time_frame>OL baseline and week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>80 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine Pulse Rate, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing Pulse Rate, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight of Female Patients, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight of Male Patients, Baseline and Week 80, Vital Signs Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS), Baseline and End of Open Label, Treated Set</measure>
    <time_frame>OL Baseline and Week 80</time_frame>
    <description>ESS Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Minnesota Impulsive Disorder Interview (mMIDI), Frequency of Patients With at Least One Abnormal Behavior, Treated Set</measure>
    <time_frame>Baseline, 80 weeks</time_frame>
    <description>The mMIDI is a semi-structured interview designed to assess impulsive control disorders. The scale was modified to focus behaviors of: pathological gambling, compulsive buying and compulsive sexual behavioral.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Pramipexole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>Pramipexole ER 0.375 -4.5 mg</description>
    <arm_group_label>Pramipexole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets identical to Pramipexole ER tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Completion of the double-blind trial 248.525

          2. Male or female patient with advanced idiopathic Parkinson's disease (PD), with a
             Modified Hoehn and Yahr stage of 2 to 4 at on-time, and a concomitant treatment with
             standard or controlled release L-Dopa+, or a combination of L-Dopa+ and entacapone.

          3. Patient willing and able to comply with scheduled visits, treatment plan, laboratory
             tests and other study procedures. In particular the patient should be able to
             recognise the off-time and on-time periods during waking hours and the patient (or a
             family member or a guardian) should be able to record them accurately in the patient
             diary.

          4. Signed informed consent obtained before any study procedures are carried out (in
             accordance with International Conference of Harmonization - Good Clinical Practice
             (ICH-GCP) guidelines and local legislation).

        Exclusion criteria:

          1. Patients prematurely withdrawn from the double-blind trial 248.525

          2. Atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis or
             degenerative diseases

          3. Any psychiatric disorder according to Diagnostic and Statistical Manual of Mental
             Disorders (DSM)-IV criteria that could prevent compliance or completion of the study
             and/or put the patient at risk if he/she takes part in the study

          4. History of psychosis, except history of drug induced hallucinations

          5. History of deep brain stimulation

          6. Clinically significant ECG abnormalities at baseline

          7. Clinically significant hypotension and/or symptomatic orthostatic hypotension at
             baseline

          8. Malignant melanoma or history of previously treated malignant melanoma

          9. Any other clinically significant disease, whether treated or not, that could put the
             patient at risk or could prevent compliance or completion of the study

         10. Pregnancy or breast-feeding

         11. Sexually active female of childbearing potential not using a medically approved method
             of birth control

         12. Serum levels of aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase
             (SGOT)), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase) (SGPT)),
             alkaline phosphatase (AP) or bilirubin &gt; 2 upper limit normal (ULN) at baseline

         13. Patients with a creatinine clearance &lt; 50 mL/min at baseline

         14. Any medication with central dopaminergic antagonist activity within 4 weeks prior to
             the baseline visit

         15. Any of the following drugs within 4 weeks prior to baseline visit: methylphenidate,
             cinnarizine, amphetamines

         16. Flunarizine within 3 months prior to baseline

         17. Known hypersensitivity to pramipexole or its excipients

         18. Drug abuse, according to investigators judgement, within 2 years prior to baseline

         19. Participation in investigational drug studies other than the trial 248.525, or use of
             other investigational drugs within one month or five times the half-life of the
             investigational drug (whichever is longer) prior to baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>32 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>248.634.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rakovnik</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valasske Mezirici</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karnataka</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grosseto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Napolii</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cruz, Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ermita, Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.63208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.48003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubnica nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alcorcon (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Cugat del Valles (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarrasa (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nyköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackburn</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>248.634.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <results_first_submitted>June 16, 2011</results_first_submitted>
  <results_first_submitted_qc>June 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2011</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PPX ER (Previous Placebo)</title>
          <description>Pramipexole ER Treatment with placebo in previous trial</description>
        </group>
        <group group_id="P2">
          <title>PPX ER (Previous PPX ER)</title>
          <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
        </group>
        <group group_id="P3">
          <title>PPX ER (Previous PPX IR)</title>
          <description>Pramipexole ER Treatment with Pramipexole Immediate Release (IR) in previous trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="123"/>
                <participants group_id="P3" count="139"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set, all patients dispensed study drug and documented to have taken at least one dose</population>
      <group_list>
        <group group_id="B1">
          <title>PPX ER (Previous Placebo)</title>
          <description>Pramipexole ER Treatment with placebo in previous trial</description>
        </group>
        <group group_id="B2">
          <title>PPX ER (Previous PPX ER)</title>
          <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
        </group>
        <group group_id="B3">
          <title>PPX ER (Previous PPX IR)</title>
          <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="139"/>
            <count group_id="B4" value="391"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="9.7"/>
                    <measurement group_id="B2" value="61.7" spread="9.8"/>
                    <measurement group_id="B3" value="61.8" spread="9.7"/>
                    <measurement group_id="B4" value="61.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Patients Successfully Switched From Pramipexole (PPX) IR or ER to ER Assessed on UPDRS II+III</title>
        <description>Unified Parkinson’s Disease Rating Scale (UPDRS) Successfully switched means: UPDRS II+III baseline score &gt;20 without a relative worsening of UPDRS II+III score &gt; 15% from baseline or UPDRS II+III baseline score &lt;=20 without an absolute worsening of UPDRS II+III score &gt; 3 from baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
        <time_frame>One week</time_frame>
        <population>Patients from Full Analysis Set (FAS included all patients who were dispensed study medication, had received at least one dose of study drug and had provided any post-baseline efficacy assessment) and who maintain the final dose of the previous study</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Successfully Switched From Pramipexole (PPX) IR or ER to ER Assessed on UPDRS II+III</title>
          <description>Unified Parkinson’s Disease Rating Scale (UPDRS) Successfully switched means: UPDRS II+III baseline score &gt;20 without a relative worsening of UPDRS II+III score &gt; 15% from baseline or UPDRS II+III baseline score &lt;=20 without an absolute worsening of UPDRS II+III score &gt; 3 from baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
          <population>Patients from Full Analysis Set (FAS included all patients who were dispensed study medication, had received at least one dose of study drug and had provided any post-baseline efficacy assessment) and who maintain the final dose of the previous study</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS II+III Change From Open Label (OL) Baseline</title>
        <description>UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
        <time_frame>OL Baseline and week 80</time_frame>
        <population>Patients from FAS with values of UPDRS II+III at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS II+III Change From Open Label (OL) Baseline</title>
          <description>UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
          <population>Patients from FAS with values of UPDRS II+III at week 80</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="1.5"/>
                    <measurement group_id="O2" value="1.1" spread="1.6"/>
                    <measurement group_id="O3" value="2.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PPX ER versus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0039</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with factors treatment and country and covariate OL baseline</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PPX IR versus Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with factors treatment and country and covariate OL baseline</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With UPDRS II+III Response</title>
        <description>A response means an improvement of &gt;=20% in UPDRS II+III from OL baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
        <time_frame>Week 80</time_frame>
        <population>Patients from FAS with values of UPDRS II+III at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With UPDRS II+III Response</title>
          <description>A response means an improvement of &gt;=20% in UPDRS II+III from OL baseline UPDRS II+III ranging from 0 (normal) to 160 (severe). UPDRS part II measures activities of daily living, part III measures motor symptoms</description>
          <population>Patients from FAS with values of UPDRS II+III at week 80</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Successfully Switched From PPX IR or ER to ER Assessed on Off-time</title>
        <description>A patient was considered as successfully switched if he/she has converted to ER without a worsening of off time by more than 12.5% from baseline. Off-time is based on patient diary data and describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).</description>
        <time_frame>One week</time_frame>
        <population>Patients from FAS and who maintain the final dose of the previous study</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Successfully Switched From PPX IR or ER to ER Assessed on Off-time</title>
          <description>A patient was considered as successfully switched if he/she has converted to ER without a worsening of off time by more than 12.5% from baseline. Off-time is based on patient diary data and describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).</description>
          <population>Patients from FAS and who maintain the final dose of the previous study</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Off Time During Waking Hours Total Score: Change From Baseline</title>
        <description>Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
A negative change implies improvement</description>
        <time_frame>Baseline and week 80</time_frame>
        <population>Patients from FAS with values of UPDRS II+III at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Off Time During Waking Hours Total Score: Change From Baseline</title>
          <description>Percentage off-time based on patient diary data, percentage ranging from 0 (best case) to 100 (worst case). Off-time describes a period when the patient experiences increased parkinsonian symptoms (e.g. immobility or inability to move with ease).
A negative change implies improvement</description>
          <population>Patients from FAS with values of UPDRS II+III at week 80</population>
          <units>percentage during waking hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.0"/>
                    <measurement group_id="O2" value="-0.3" spread="2.1"/>
                    <measurement group_id="O3" value="1.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5590</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1289</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response in Percentage Off Time During Waking Hours</title>
        <description>Response means &gt;=20% improvement relative to OL baseline in the % off-time during waking hours</description>
        <time_frame>80 weeks</time_frame>
        <population>Patients from FAS with values of off time during waking hours at 80 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
          <group group_id="O4">
            <title>Total PPX ER</title>
            <description>Pramipexole ER, all patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response in Percentage Off Time During Waking Hours</title>
          <description>Response means &gt;=20% improvement relative to OL baseline in the % off-time during waking hours</description>
          <population>Patients from FAS with values of off time during waking hours at 80 weeks</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage on Time Without Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
        <description>Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement.</description>
        <time_frame>Baseline and week 80</time_frame>
        <population>Patients from FAS with values of on time during waking hours at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage on Time Without Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
          <description>Percentage on-time based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement.</description>
          <population>Patients from FAS with values of on time during waking hours at week 80</population>
          <units>percentage during waking hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.5"/>
                    <measurement group_id="O2" value="2.9" spread="2.7"/>
                    <measurement group_id="O3" value="-2.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1073</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8694</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage on Time With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
        <description>Percentage on-time with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
        <time_frame>Baseline and week 80</time_frame>
        <population>Patients from FAS with values of on time during waking hours at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage on Time With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
          <description>Percentage on-time with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
          <population>Patients from FAS with values of on time during waking hours at week 80</population>
          <units>percentage during waking hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.8"/>
                    <measurement group_id="O2" value="-2.7" spread="1.9"/>
                    <measurement group_id="O3" value="0.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0573</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage on Time Without Dyskinesia or With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
        <description>Percentage on-time without dyskinesia or with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
        <time_frame>Baseline and week 80</time_frame>
        <population>Patients from FAS with values of on time during waking hours at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage on Time Without Dyskinesia or With Non Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
          <description>Percentage on-time without dyskinesia or with non troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
          <population>Patients from FAS with values of on time during waking hours at week 80</population>
          <units>percentage during waking hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.2"/>
                    <measurement group_id="O2" value="0.7" spread="2.3"/>
                    <measurement group_id="O3" value="-0.9" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6434</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2469</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage on Time With Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
        <description>Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
        <time_frame>Baseline and week 80</time_frame>
        <population>Patients from FAS with values of on time during waking hours at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage on Time With Troublesome Dyskinesia During Waking Hours: Change From Baseline After 80 Weeks</title>
          <description>Percentage on-time with troublesome dyskinesia based on patient diary data, percentage ranging from 0 (worst case) to 100 (best case). On-time describes a period when the patient has no symptoms of off-time and is not asleep. A positive change implies improvement</description>
          <population>Patients from FAS with values of on time during waking hours at week 80</population>
          <units>percentage during waking hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.0"/>
                    <measurement group_id="O2" value="-0.3" spread="1.1"/>
                    <measurement group_id="O3" value="-0.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9741</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7620</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response in CGI-I</title>
        <description>Clinical Global Impression of Improvement (CGI-I), CGI-I scores ranging from '1' (very much improved) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much improved&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much improved were considered as responders</description>
        <time_frame>32 weeks</time_frame>
        <population>Patients from FAS with values of CGI-I at week 32</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
          <group group_id="O4">
            <title>Total PPX ER</title>
            <description>Pramipexole ER, all patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response in CGI-I</title>
          <description>Clinical Global Impression of Improvement (CGI-I), CGI-I scores ranging from '1' (very much improved) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much improved&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much improved were considered as responders</description>
          <population>Patients from FAS with values of CGI-I at week 32</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response in PGI-I</title>
        <description>Patient Global Impression of Improvement (PGI-I), PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders</description>
        <time_frame>32 weeks</time_frame>
        <population>Patients from FAS with values of PGI-I at week 32</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
          <group group_id="O4">
            <title>Total PPX ER</title>
            <description>Pramipexole ER, all patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response in PGI-I</title>
          <description>Patient Global Impression of Improvement (PGI-I), PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders</description>
          <population>Patients from FAS with values of PGI-I at week 32</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="363"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response in PGI-I for Early Morning Off Symptoms</title>
        <description>Patient Global Impression of Improvement (PGI-I) for early morning off symptoms, PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders</description>
        <time_frame>32 weeks</time_frame>
        <population>Patients from FAS with values of PGI-I for early morning off symptoms at week 32</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
          <group group_id="O4">
            <title>Total PPX ER</title>
            <description>Pramipexole ER, all patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response in PGI-I for Early Morning Off Symptoms</title>
          <description>Patient Global Impression of Improvement (PGI-I) for early morning off symptoms, PGI-I scores ranging from '1' (very much better) to '7' (very much worse). For patients previously treated with Placebo, all patients with at least &quot;much better&quot; were considered as responders. For patients previously treated with PPX ER or IR, all patients with no change to very much better were considered as responders</description>
          <population>Patients from FAS with values of PGI-I for early morning off symptoms at week 32</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS I Total Score and Change From OL Baseline at Week 80</title>
        <description>UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood</description>
        <time_frame>OL baseline and week 80</time_frame>
        <population>Patients from FAS with values of UPDRS I at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS I Total Score and Change From OL Baseline at Week 80</title>
          <description>UPDRS I ranging from 0 (normal) to 16 (severe). UPDRS I measures Mentation, Behavior and Mood</description>
          <population>Patients from FAS with values of UPDRS I at week 80</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.5" spread="0.2"/>
                    <measurement group_id="O3" value="0.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0831</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0759</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS II Total Score and Change From OL Baseline at Week 80</title>
        <description>UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities</description>
        <time_frame>OL baseline and week 80</time_frame>
        <population>Patients from FAS with values of UPDRS II at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS II Total Score and Change From OL Baseline at Week 80</title>
          <description>UPDRS II ranging from 0 (normal) to 52 (severe). UPDRS Part II is calculated as the average of UPDRS part II at on and UPDRS part II at off-period for each of the 13 activities</description>
          <population>Patients from FAS with values of UPDRS II at week 80</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.5"/>
                    <measurement group_id="O2" value="0.4" spread="0.6"/>
                    <measurement group_id="O3" value="1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1713</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0130</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS III Total Score and Change From OL Baseline at Week 80</title>
        <description>UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms</description>
        <time_frame>OL baseline and week 80</time_frame>
        <population>Patients from FAS with values of UPDRS III at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS III Total Score and Change From OL Baseline at Week 80</title>
          <description>UPDRS III ranging from 0 (normal) to 108 (severe). UPDRS part III measures motor symptoms</description>
          <population>Patients from FAS with values of UPDRS III at week 80</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="1.1"/>
                    <measurement group_id="O2" value="0.7" spread="1.1"/>
                    <measurement group_id="O3" value="1.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UPDRS IV Total Score and Change From OL Baseline at Week 80</title>
        <description>UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy</description>
        <time_frame>OL baseline and week 80</time_frame>
        <population>Patients from FAS with values of UPDRS IV at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>UPDRS IV Total Score and Change From OL Baseline at Week 80</title>
          <description>UPDRS IV ranging from 0 (normal) to 23 (severe). UPDRS IV measures complications of therapy</description>
          <population>Patients from FAS with values of UPDRS IV at week 80</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="-0.0" spread="0.3"/>
                    <measurement group_id="O3" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8760</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5113</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson Fatigue Scale (PFS-16) Score and Change From OL Baseline at Week 80</title>
        <description>PFS-16 (Parkinson fatigue scale) ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD</description>
        <time_frame>OL baseline and week 80</time_frame>
        <population>Patients from FAS with values of PFS-16 score at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson Fatigue Scale (PFS-16) Score and Change From OL Baseline at Week 80</title>
          <description>PFS-16 (Parkinson fatigue scale) ranging from 16 (better perceived health status) to 80 (severe symptoms of the disease) measuring aspects of fatigue that are relevant to patients with PD</description>
          <population>Patients from FAS with values of PFS-16 score at week 80</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.5"/>
                    <measurement group_id="O2" value="3.8" spread="1.6"/>
                    <measurement group_id="O3" value="3.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0148</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0201</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance with factors for treatment, country and baseline as a covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With L-dopa Daily Dose Change: Change From OL Baseline at Week 80</title>
        <time_frame>OL baseline and week 80</time_frame>
        <population>Patients from FAS with documentation of levodopa (L-DOPA) daily dose at week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
          <group group_id="O4">
            <title>Total PPX ER</title>
            <description>Pramipexole ER, all patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With L-dopa Daily Dose Change: Change From OL Baseline at Week 80</title>
          <population>Patients from FAS with documentation of levodopa (L-DOPA) daily dose at week 80</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Changes in Pramipexole Doses After 80 Weeks Compared to Pramipexole Dose at OL Baseline</title>
        <time_frame>OL baseline and week 80</time_frame>
        <population>Patients from Treated Set (all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment) and treated until week 80</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
          <group group_id="O4">
            <title>Total PPX ER</title>
            <description>Pramipexole ER, all patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Changes in Pramipexole Doses After 80 Weeks Compared to Pramipexole Dose at OL Baseline</title>
          <population>Patients from Treated Set (all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment) and treated until week 80</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="126"/>
                <count group_id="O4" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <time_frame>80 weeks</time_frame>
        <population>The Treated Set (TS) included all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
          <group group_id="O4">
            <title>Total PPX ER</title>
            <description>Pramipexole ER, all patients</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <population>The Treated Set (TS) included all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="391"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events</title>
        <description>The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in advanced Parkinson's Disease (PD) (248.525 (NCT00466167)). Therefore these items were considered as a safety evaluation.</description>
        <time_frame>80 weeks</time_frame>
        <population>Patients from Treated Set (defined as all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with matching placebo in previous trial (NCT00466167)</description>
          </group>
          <group group_id="O2">
            <title>PPX ER</title>
            <description>Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX IR</title>
            <description>Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Adverse Events, Adverse Drug Reactions, Serious Adverse Events</title>
          <description>The aim of this study was to obtain long-term safety and tolerability data on pramipexole ER, in patients who have previously completed a pramipexole double blind study in advanced Parkinson's Disease (PD) (248.525 (NCT00466167)). Therefore these items were considered as a safety evaluation.</description>
          <population>Patients from Treated Set (defined as all patients who were dispensed study drug and were documented to have at least one dose of investigational treatment)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Patients with Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3"/>
                    <measurement group_id="O2" value="83.7"/>
                    <measurement group_id="O3" value="79.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Patients with Adverse Drug Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Patients with Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="8.9"/>
                    <measurement group_id="O3" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supine Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Supine Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" spread="8.9"/>
                    <measurement group_id="O2" value="77.3" spread="8.6"/>
                    <measurement group_id="O3" value="77.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" spread="8.9"/>
                    <measurement group_id="O2" value="78.3" spread="8.9"/>
                    <measurement group_id="O3" value="77.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standing Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Standing Diastolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="9.2"/>
                    <measurement group_id="O2" value="77.3" spread="9.1"/>
                    <measurement group_id="O3" value="77.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="9.1"/>
                    <measurement group_id="O2" value="78.1" spread="9.3"/>
                    <measurement group_id="O3" value="76.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supine Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Supine Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" spread="12.2"/>
                    <measurement group_id="O2" value="124.5" spread="15.4"/>
                    <measurement group_id="O3" value="125.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.2" spread="13.5"/>
                    <measurement group_id="O2" value="123.8" spread="14.2"/>
                    <measurement group_id="O3" value="124.4" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standing Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Standing Systolic Blood Pressure, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.2" spread="13.9"/>
                    <measurement group_id="O2" value="121.1" spread="16.4"/>
                    <measurement group_id="O3" value="120.9" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.9" spread="15.0"/>
                    <measurement group_id="O2" value="121.6" spread="14.3"/>
                    <measurement group_id="O3" value="120.5" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supine Pulse Rate, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Supine Pulse Rate, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" spread="9.6"/>
                    <measurement group_id="O2" value="72.6" spread="9.2"/>
                    <measurement group_id="O3" value="73.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="9.0"/>
                    <measurement group_id="O2" value="74.2" spread="7.9"/>
                    <measurement group_id="O3" value="74.4" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standing Pulse Rate, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Standing Pulse Rate, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" spread="10.7"/>
                    <measurement group_id="O2" value="78.0" spread="9.5"/>
                    <measurement group_id="O3" value="77.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" spread="8.7"/>
                    <measurement group_id="O2" value="77.7" spread="7.5"/>
                    <measurement group_id="O3" value="78.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight of Female Patients, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight of Female Patients, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="13.0"/>
                    <measurement group_id="O2" value="61.7" spread="14.0"/>
                    <measurement group_id="O3" value="63.8" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" spread="13.8"/>
                    <measurement group_id="O2" value="61.7" spread="15.0"/>
                    <measurement group_id="O3" value="63.6" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight of Male Patients, Baseline and Week 80, Vital Signs Treated Set</title>
        <time_frame>OL Baseline and Week 80</time_frame>
        <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight of Male Patients, Baseline and Week 80, Vital Signs Treated Set</title>
          <population>Vital Signs Treated Set - All participants treated with study drug and have both baseline and week 80 vital sign data</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="15.7"/>
                    <measurement group_id="O2" value="72.1" spread="12.2"/>
                    <measurement group_id="O3" value="70.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="16.4"/>
                    <measurement group_id="O2" value="72.7" spread="12.5"/>
                    <measurement group_id="O3" value="72.0" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale (ESS), Baseline and End of Open Label, Treated Set</title>
        <description>ESS Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)</description>
        <time_frame>OL Baseline and Week 80</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale (ESS), Baseline and End of Open Label, Treated Set</title>
          <description>ESS Total score ranges from zero (best) to 24 (worst); scale has 8 items, each rated from zero (no chance of dozing) to 3 (high chance of dozing)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OL Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="4.6"/>
                    <measurement group_id="O2" value="8.1" spread="4.1"/>
                    <measurement group_id="O3" value="8.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at end of OL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.1"/>
                    <measurement group_id="O2" value="1.2" spread="4.7"/>
                    <measurement group_id="O3" value="1.2" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Minnesota Impulsive Disorder Interview (mMIDI), Frequency of Patients With at Least One Abnormal Behavior, Treated Set</title>
        <description>The mMIDI is a semi-structured interview designed to assess impulsive control disorders. The scale was modified to focus behaviors of: pathological gambling, compulsive buying and compulsive sexual behavioral.</description>
        <time_frame>Baseline, 80 weeks</time_frame>
        <population>Treated Set - all patients dispensed drug and documented to have taken at least one dose</population>
        <group_list>
          <group group_id="O1">
            <title>PPX ER (Previous Placebo)</title>
            <description>Pramipexole ER Treatment with placebo in previous trial</description>
          </group>
          <group group_id="O2">
            <title>PPX ER (Previous PPX ER)</title>
            <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
          </group>
          <group group_id="O3">
            <title>PPX ER (Previous PPX IR)</title>
            <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Minnesota Impulsive Disorder Interview (mMIDI), Frequency of Patients With at Least One Abnormal Behavior, Treated Set</title>
          <description>The mMIDI is a semi-structured interview designed to assess impulsive control disorders. The scale was modified to focus behaviors of: pathological gambling, compulsive buying and compulsive sexual behavioral.</description>
          <population>Treated Set - all patients dispensed drug and documented to have taken at least one dose</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal behavior - pathological gambling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal behavior - compulsive buying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal behavior - compulsive sexual behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>80 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PPX ER (Previous Placebo)</title>
          <description>Pramipexole ER Treatment with placebo in previous trial</description>
        </group>
        <group group_id="E2">
          <title>PPX ER (Previous PPX ER)</title>
          <description>Pramipexole ER Treatment with Pramipexole ER in previous trial</description>
        </group>
        <group group_id="E3">
          <title>PPX ER (Previous PPX IR)</title>
          <description>Pramipexole ER Treatment with Pramipexole IR in previous trial</description>
        </group>
        <group group_id="E4">
          <title>Total PPX ER</title>
          <description>Pramipexole ER, all patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rectal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Eyeball rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>On and off phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac neurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Paramnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pathological gambling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="242" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="106" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="391"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="123"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="391"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

